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PURPOSE. Over a third of patients with Acanthamoeba keratitis (AK) experience severe
inflammatory complications (SICs). This study aimed to determine if some contact lens
(CL) wearers with AK were predisposed to SICs due to variations in key immune genes.
METHODS. CL wearers with AK who attended Moorfields Eye Hospital were recruited
prospectively between April 2013 and October 2014. SICs were defined as scleritis and/or
stromal ring infiltrate. Genomic DNA was processed with an Illumina Low Input Custom
Amplicon assay of 58 single nucleotide polymorphism (SNP) targets across 18 genes and
tested for association in PLINK.
RESULTS. Genomic DNA was obtained and analyzed for 105 cases of AK, 40 (38%) of whom
experienced SICs. SNPs in the CXCL8 gene encoding IL-8 was significantly associated with
protection from SICs (chr4: rs1126647, odds ratio [OR] = 0.3, P = 0.005, rs2227543, OR =
0.4, P = 0.007, and rs2227307, OR = 0.4, P = 0.02) after adjusting for age, sex, steroids
prediagnosis, and herpes simplex keratitis (HSK) misdiagnosis. Two TLR-4 SNPs were
associated with increased risk of SICs (chr9: rs4986791 and rs4986790, both OR = 6.9,
P = 0.01). Th-17 associated SNPs (chr1: IL-23R rs11209026, chr2: IL-1β rs16944, and
chr12: IL-22 rs1179251) were also associated with SICs.
CONCLUSIONS. The current study identifies biologically relevant genetic variants in patients
with AK with SICs; IL-8 is associated with a strong neutrophil response in the cornea
in AK, TLR-4 is important in early AK disease, and Th-17 genes are associated with
adaptive immune responses to AK in animal models. Genetic screening of patients with
AK to predict severity is viable and this would be expected to assist disease management.
Keywords: Acanthamoeba keratitis (AK), adaptive, complications, genetic susceptibility,
inflammation, innate, keratitis, scleritis
Acanthamoeba keratitis (AK) results in the mostprolonged and severe morbidity of any of the causes of
acute microbial keratitis.1 Unlike other Acanthamoeba infec-
tions, which usually affect immunocompromised patients,
AK occurs in immunocompetent healthy individuals.2 Treat-
ment failure rates are currently in the order of 50% for a poor
outcome (acuity less ≤ 20/80 ± surgery) with median overall
cure times in the order of 5 months3,4 and 25% of patients
requiring more than 9 months of treatment.3 Over 25% of
patients in large series have required a keratoplasty.5,6
One of the major causes of morbidity in AK is the severe
inflammatory response that develops in some patients.7 This
occurs in both the infected cornea, with the development
of a corneal ring infiltrate, as well as in the usually nonin-
fected adjacent sclera. Scleritis causes both severe pain, and,
in some cases, the secondary complications of scleral thin-
ning, choroidal detachment, and hypotony.8–11 Corneal ring
infiltrates are reported in 13 to 24% of cases and scleritis in
9 to 18% of patients with AK.8,12,13 These severe inflamma-
tory complications are associated with poor outcomes.7
We and others have shown that single nucleotide poly-
morphisms (SNPs) of inflammatory genes involved in animal
models of bacterial keratitis are associated with the onset
and severity of corneal infection in patients who wear
contact lenses (CLs).14–18 CL wear is the major risk factor
for AK in developed countries, accounting for around 90%
of cases.19 This study was designed to test our hypothe-
sis that differences in immune gene variation in otherwise
healthy CL wearers determine whether a severe inflamma-
tory response develops in the course of AK.
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TABLE 1. Distribution of Sample, Presenting History, and Clinical Features of Patients With and Without Severe Inflammatory Complications
SICs Non-SICs
Characteristics N = 40 N = 65 P Value
Age at diagnosis, mean y ± SD (n = 89) 38.3 ± 17.3 37.9 ± 16.2 0.906
Sex, n (%) (n = 105)
M 20 (50.0) 30 (46.2) 0.841
F 20 (50.0) 35 (53.8)
Topical corticosteroid use prior to AAT n (%) (n = 95)
No 23 (67.6) 52 (85.2) 0.065
Yes 11 (32.4) 9 (14.8)
HSV keratitis treatment prior to AAT (n = 95)
No 20 (58.8) 48 (78.7) 0.057
Yes 14 (41.2) 13 (21.3)
Bacterial keratitis treatment prior to AAT n (%) (n = 95)
No 13 (38.2) 25 (41.0) 0.830
Yes 21 (61.8) 36 (59.0)
Patients referred to tertiary care (%) (n = 103)
No 19 (47.5) 37 (58.7) 0.313
Yes 21 (52.5) 26 (41.3)
Disease stage at presentationa (%) (n = 84)
1 5 (18.5) 25 (43.9) <0.001
2 9 (33.3) 31 (54.4)
3 13 (48.1) 1 (1.8)
AAT = anti-amoebic therapy; HSV = herpes simplex virus.
a Stage 1 corneal epitheliopathy; stage 2, stage 1 + epithelial defect, perineural infiltrate or stromal infiltrate; and stage 3, stage 2 +
corneal ring infiltrate.
METHODS
This was a prospective study of patients with CL associ-
ated AK classified as either displaying a severe inflammatory
complication (SICs) or not (non-SICs).
Ethics
The protocol was approved by the London-Hampstead
National Research Ethics Service (Reference 13/LO/0032)
and Moorfields Eye Hospital Research Management Commit-
tee. The trial was adopted by the UK National Institute for
Health Research, Clinical Research Network Portfolio. All
participants gave written informed consent and all study
procedures conformed to the tenets of the Declaration of
Helsinki.
Recruitment
CL wearers who attended Moorfields Eye Hospital for diag-
nosis and/or ongoing treatment for AK were recruited
prospectively between April 2013 and October 2014.
For the diagnosis of AK, one or more of the following
criteria was satisfied:
1. A positive Acanthamoeba culture or histopathologic
confirmation of trophozoites or cysts.
2. Culture-negative cases that were positively identi-
fied as having Acanthamoeba cysts on confocal
microscopy, together with a typical clinical course and
response to anti-amoebic treatment (AAT).
3. In the absence of criterion 1 or 2, patients with
perineural corneal infiltrates or a typical clinical
course with a response to AAT.
Genomic DNA was collected by a self-administered cheek
swab (FLOQswabs; Copan Diagnostics, CA, USA) or a saliva
kit (DNAGenotek, Ontario, Canada or DNAgard, Biomatri-
cia, CA, USA). Age, sex, and ethnicity was collected via
self-report. Clinical data were collected retrospectively from
the patients’ with AK hospital records using the REDCap
database platform (Vanderbilt University, Nashville, TN,
USA).
Disease stage at presentation of AK was divided into
3 categories: stage 1, corneal epitheliopathy only; stage
2, presence of one or more of corneal epithelial defects,
perineural infiltrates or stromal infiltrates, in addition to
stage 1 findings; and stage 3, presence of a corneal stromal
ring infiltrate in addition to one or more features of stage 2
disease.20
Severe Inflammatory Complications
SICs were defined as documentation of scleritis and/or stro-
mal ring infiltrate in the patients’ hospital records in accor-
dance with a previous study.7
SNP Assay Design
Much of the understanding of the immune response to Acan-
thamoeba has come from studies in animal models. These
studies indicate that innate cells and proteins, such as TLR-4,
IL-8, and neutrophils21,22 are crucial to mount a response in
early AK disease, and that Th17 cells are involved in limit-
ing disease severity.23 We therefore designed a SNP assay
targeting Th-17 pathway genes (IL17-A, IL17-F, IL17-R, IL-
1β, TNFα, TGFβ, IFNγ , IL-6, IL-23R, IL-22, and IL-27) and
CXCL8 (encodes for IL-8). We also included Th-1 and Th-2
interleukins genes found associated with bacterial keratitis
(IL-12 and IL-10, respectively) and a novel cytokine (IL-18).
Surface defense proteins defensin 1 and TLR-4 were further
targeted, as expression of these proteins are upregulated
in the presence of Acanthamoeba in both animal models
and in vitro.24 As a SNP of TNF-related apoptosis-inducing
ligand receptor (TRAIL-R1), a negative modulator of
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TABLE 2. Allelic Frequencies of Targeted SNPs and Association Analysis in Patients With AK With Severe Inflammatory Complications (SICs)
Compared to Those Without
MAF (A1)






A2/A1 SIC Non-SIC OR P Value
IL10/IL-10 rs1800872 1:206773062 G/T 0.175 0.285 0.595 0.192
rs1800871 1:206773289 G/A 0.175 0.292 0.569 0.160
rs1800896 1:206773552 T/C 0.375 0.385 0.909 0.784
rs1800890 1:206776020 A/T 0.288 0.300 0.836 0.643
IL23R/IL-23R rs1884444 1:67168129 G/T 0.075 0.077 0.983 0.970
rs7517847 1:67215986 T/G 0.450 0.346 2.035 0.073
rs2201841 1:67228519 A/G 0.263 0.323 0.884 0.742
rs11209026 1:67240275 G/A 0.113 0.031 6.294 0.015
rs11465817 1:67255414 C/A 0.238 0.308 0.858 0.681
rs10889677 1:67259437 C/A 0.288 0.323 0.884 0.742
IL1B/IL-1β rs1143634 2:112832813 G/A 0.250 0.208 1.045 0.923
rs16944 2:112837290 G/A 0.275 0.362 0.438 0.031
CXCL8/IL-8 rs4073 4:73740307 T/A 0.413 0.508 0.508 0.0703
rs2227307 4:73740952 T/G 0.350 0.500 0.411 0.019
rs2227549 4:73741020 A/G 0.038 0.038 1.160 0.834
rs2227306 4:73741338 C/T 0.288 0.439 0.495 0.053
rs2227543 4:73742193 C/T 0.263 0.469 0.365 0.007
rs1126647 4:73743328 A/T 0.250 0.462 0.336 0.005
IL12B/IL-12 B rs3212227 5:159315942 T/G 0.125 0.231 0.554 0.200
rs10045431 5:159387525 C/A 0.300 0.339 0.775 0.466
rs6887695 5:159395637 G/C 0.338 0.331 0.947 0.874
TNFα/TNFα rs1800629 6:31575254 G/A 0.188 0.123 1.497 0.334
IL17A/IL-17A rs2275913 6:52186235 G/A 0.300 0.377 0.842 0.588
rs3748067 6:52190541 C/T 0.088 0.085 0.982 0.975
IL17F/IL-17F rs763780 6:52236941 T/C 0.050 0.031 2.330 0.279
rs2397084 6:52237046 T/C 0.100 0.100 0.944 0.926
IL6/IL-6 rs1800797 7:22726602 G/A 0.313 0.369 0.750 0.415
rs1800796 7:22726627 G/C 0.113 0.108 1.074 0.886
rs1800795 7:22727026 G/C 0.313 0.369 0.846 0.629
DEFB1/DEFβ1 rs1800972 8:6877901 G/C 0.175 0.246 0.701 0.395
rs1799946 8:6877909 C/T 0.375 0.346 1.349 0.437
rs2702877 8:6878545 C/G 0.275 0.269 1.020 0.957
rs5743409 8:6879098 C/A 0.425 0.423 0.937 0.841
TRAIL-R1/TNFRSF10A rs20576 8:23200707 T/G 0.175 0.185 1.253 0.605
rs20575 8:23201811 G/C 0.375 0.485 0.739 0.346
rs6557634 8:23202743 C/T 0.363 0.477 0.711 0.284
TLR4/TL-R4 rs10983755 9:117702392 A/G 0.038 0.015 4.065 0.282
rs10759932 9:117702866 T/C 0.163 0.162 0.785 0.630
rs11536879 9:117709933 A/G 0.038 0.054 0.808 0.787
rs1927907 9:117710486 C/T 0.150 0.169 0.814 0.674
rs4986790 9:117713024 A/G 0.100 0.031 6.915 0.014
rs4986791 9:117713324 C/T 0.113 0.031 6.915 0.014
rs11536889 9:117715853 G/C 0.163 0.162 0.780 0.593
rs7873784 9:117716658 G/C 0.175 0.169 1.412 0.403
IL18/IL-18 rs187238 11:112164265 C/G 0.250 0.269 0.761 0.512
IFNγ /IFNγ rs2069718 12:68156382 G/A 0.425 0.369 1.302 0.445
rs1861494 12:68157629 T/C 0.300 0.300 0.935 0.826
rs2430561 12:68158742 T/A 0.463 0.462 1.109 0.755
IL22/IL-22 rs1179251 12:68251271 C/G 0.025 0.131 0.0620 0.014
rs2227485 12:68253933 A/G 0.475 0.408 1.216 0.567
rs2227478 12:68254842 A/G 0.400 0.292 1.996 0.0665
rs2227473 12:68255258 C/T 0.113 0.131 1.243 0.666
rs2227472 12:68255353 C/T 0.463 0.415 1.174 0.634
IL27/IL-27 rs4788084 16:28528527 C/T 0.375 0.323 1.294 0.423
TGFB1/TGFβ rs1800471 19:41352971 C/G 0.063 0.085 0.530 0.353
rs1800469 19:41354391 G/A 0.313 0.277 1.178 0.666
IL17RA/IL-17RA rs4819554 22:17084145 A/G 0.238 0.192 1.428 0.387
rs2229151 22:17108407 G/A 0.025 0.023 1.288 0.758
Statistically significant differences in bold typeface.
MAF = minor allele frequency.
a SICS versus age at diagnosis, sex, topical corticosteroid use prior to anti-amoebic therapy and HSV keratitis treatment prior to anti-
amoebic therapy.
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CXCL8/IL8 rs2227543 C/T4:73742193 TT 3 (7.5) 14 (21.5) 0.0145
TC 15 (37.5) 33 (50.8)
CC 22 (55.0) 18 (27.7)
rs1126647 A/T4:73743328 TT 2 (5.0) 14 (21.5) 0.0111
TA 16 (40.0) 32 (49.2)
AA 22 (55.0) 19 (29.2)
TLR4/TLR4 rs4986790 A/G9:117713024 GG 0 0 0.0541
GA 8 (20.0) 4 (6.2)
AA 32 (80.0) 61 (93.8)
rs4986791 C/T9:117713324 TT 0 0 0.0290
TC 9 (22.5) 4 (6.2)
CC 31 (77.5) 61 (93.8)
FIGURE. Linkage disequilibrium structure of selected SNPs in regions of interest in CXCL8 (encodes IL-8) (A) and TLR-4 (B). LD blocks were
created with the default algorithm in HaploView program (version 4.1) that creates 95% confidence bounds on the normalized coefficient of
linkage disequilibrium (D′) considered being in strong LD where 95% of the comparisons made are informative. The coloring of the boxes
depends on two scores, the logarithm of the odds (LOD) and D′, high association (LOD > = 2 and D′ = 1, red), low association (LOD < 2
and D′ = 1, blue), and no association (LOD < 2 and D′ < 1, white). LOD score are shown within the box if D′ < 1.
inflammation, has recently been associated with trachoma
infection in humans25 and it was also included in the SNP
panel.
Following collection via a cheek swab or a saliva kit,
genomic DNA was extracted and processed using the Illu-
mina MiSeq platform. Detailed gDNA sample processing
and bioinformatics methods are included in Supplementary
File S1.
SNPs and Phenotype Association Analysis
The PLINK (version 1.07) software was used for associa-
tion analysis.26 SNPs with a minor allele frequency < 0.01
in the study cohort or not conforming to Hardy-Weinberg
Equilibrium (P < 0.001) were removed. Remaining SNPs
were assessed for association with SICs using logistic regres-
sion. Topical corticosteroid use prior to the initiation of AAT,
bacterial keratitis treatment prior to AAT, herpes simplex
virus (HSV) keratitis treatment prior to AAT, disease stage at
presentation, and tertiary referral (i.e. referred from another
hospital for tertiary management at Moorfields Eye Hospi-
tal) were tested for univariate associations and included in
the multivariate model if significant (P < 0.2) along with
sex and age as covariates. Analysis of linkage disequilibrium
between multiple SNPs in the same gene was performed
using HaploView (version 4).27
RESULTS
Genomic DNA was obtained and analyzed for 105 cases of
AK, 40 (38%) of whom experienced SICs (Table 1). The aver-
age age at the time of presentation for all AK cases was
36.9 ± 15.5 years, and there was no difference in age
between those with SICs compared to those without
(38.3 ± 17.3 compared to 37.9 ± 16.2, P = 0.906). Like-
wise, there was no difference in sex between the two groups
(women: 20/40, 50% vs. 35/65, 54%, P = 0.841). “Topi-
cal corticosteroid use” and “herpes simplex virus (HSV)
keratitis treatment prior to the initiation AAT” was signif-
icant P < 0.2 and was included in the genotype model.
“Disease stage at presentation” was more advanced in the
SICs group (P < 0.001) so this variable was not included
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in the final model due to collinearity. There was no differ-
ence between “bacterial keratitis treatment prior to AAT” and
“patients referred to tertiary care” for SICs versus non-SICs
and so these characteristics were also not included in the
multivariate model.
Of the 72 targeted SNPs, 6 were not able to be sequenced
with the assay (IL1B rs1143627; IL10 rs6703630; TLR4
rs12377632; IL18 rs5744292; IL22 rs2227483; and IFNγ
rs2069707), 5 did not conform to Hardy-Weinberg Equilib-
rium (P > 0.001, IL12B rs17860508; TNFα rs1799964; IL22
rs1012356; IFNγ rs2069705; and TGFB1 rs1800470), and
three had minor allele frequencies of < 0.01 (CXCL8/IL-
8 rs2227532; TRAIL-R1 rs2230229; and IFNγ rs2069709)
in this cohort. The remaining 58 SNPs were included in
the analysis. Table 2 details the allele frequencies of the
analyzed SNPs and adjusted multivariable analysis by allele.
The adjusted analysis accounted for the a priori factors of
age at diagnosis, sex, topical corticosteroid use prior to AAT,
and HSV keratitis treatment prior to AAT. Significant asso-
ciations (adjusted P < 0.05) after adjustment for covariates
were found in SNPs in genes IL-23R, IL-1β, CXCL8, TLR-4,
and IL-22.
The highest significance was found for CXCL8 (encodes
IL-8) and TLR-4 SNPs and because an association was found
with more than one SNP for each of these genes, they were
investigated further for inheritance and linkage disequilib-
rium (LD).
Associated SNPs in CXCL8 (encodes IL-8) and TLR-4
demonstrated dominant inheritance models (Table 3). LD
was performed in HaploView (version 4) for the targeted
SNPs in CXCL8 (encodes IL-8) and TLR-4 (Fig.). All SNPs
in CXCL8 (encodes IL-8) were in LD apart from rs2227549
(4:73741020). For TLR-4 only the 2 associated SNPs were in
an LD block with low LD across the rest of the gene.
DISCUSSION
This study investigated SNPs in genes encoding innate and
adaptive immune responses thought to play key roles in the
severity of AK from in vitro and in vivo animal and human
studies. SNPs in five genes encoding biologically relevant
molecules, CXCL8 (encodes IL-8, rs2227543 C/T, rs1126647
A/T, and rs2227307 T/G, all in 3’UTR gene region) and TLR-
4 (rs4986790 A/G, rs4986791 C/T, missense coding gene
region), IL-1β (rs16944, G/A, upstream regulatory region),
IL-23R (rs11209026, G/A, missense coding gene region), and
IL-22(rs1179251, C/G, intron gene region) were identified
that were associated with SICs in AK after adjusting for
covariates. SNPs of CXCL8 (encoding IL-8) and TLR-4 had
two significantly associated SNPs, each in LD and exhibited
the strongest association with SICs.
The CXCL8 (encodes IL-8) SNPs were protective for SICs
in this population. Carriers of the minor allele (T) were
around 70% less likely to experience SICs than noncarriers in
this study. In this same AK patient cohort, increased levels
of IL-8 protein in tears were associated with more severe
AK disease.28 However, tear IL-8 levels with were not corre-
lated with specific genotypes in patients in this study (P =
0.324). Similarly, a study of sepsis susceptibility in Chinese
men29 found that the T allele for SNP rs1126647 was protec-
tive and increased levels of serum IL-8 were associated with
sepsis in their population, but found no correlation between
specific genotypes and the serum IL-8 protein levels. These
findings indicate that this SNP may not be the causal SNP
that increases the transcriptional capacity for IL-8. Other
studies have suggested that rs4073 and rs2227306 may be
causal SNPs.30 Although significance associations of these
SNPs were not found in this study, they are in LD with those
identified as significant.
IL-8 is produced in the cornea by epithelial cells,
keratocytes,31 and macrophages22 and has been shown
to be upregulated in other ocular surface diseases, such
as allergy32 and dry eye.33 IL-8 mobilizes and activates
neutrophils, which is crucial in the early stage of corneal
infection. However, activated neutrophils can also release
metalloproteinases, which can degrade the extracellular
matrix.34 This is evidenced by an immunodeficient mouse
model, which when infected with adenovirus vector encod-
ing human IL-8, results in neutrophil infiltration and corneal
ulceration.35 Thinning of the cornea and persistent epithe-
lial defects, whereas not by definition part of SICs, are often
present in severe cases of AK.19 IL-8 is produced early in
the inflammatory cycle, but unlike most other inflamma-
tory cytokines, it can remain active up to weeks at the site
of inflammation.36,37 In contrast to the transitory effect of
other proinflammatory cytokines that may last only a few
hours, IL-8 may have a sustained influence36,37 and there-
fore could be an important contributor to severe inflamma-
tory outcomes in AK. In addition, IL-8 may be repeatedly
produced by epithelial and inflammatory cells, leading to
prolonged inflammation and collateral tissue damage.
Although IL-8 may have detrimental proinflammatory
effects mediated through neutrophils, several animal stud-
ies have shown the powerful anti-acanthamoeba action
of neutrophils in the early stages of disease. Neutrophils
are chemotactic to Acanthamoeba trophozoites and cyst
lysates, and are capable of killing the organism in vitro
through myeloperoxidase (MPO).38 Upon injection of one
million Acanthamoeba castellani trophozoites into the ante-
rior chamber of a mini pig model, AK was eliminated by a
robust neutrophil response.39 Intraocular infection has only
been reported in a handful of human cases8 indicating this
neutrophil response in the anterior segment may be a factor
in limiting the organism from infecting the posterior eye in
humans.
In contrast to CXCL8, minor alleles of TLR-4 SNPs were
associated with more severe AK in this study. Carriers of the
minor allele were around 6.9 times more likely to experience
SICs than noncarriers. The two significant TLR-4 SNPs are in
almost complete LD. These SNPs are not common, however,
the non-SIC minor allele frequencies are similar to popu-
lation controls (minor allele frequency 0.06 from phase III
1000 Genomes) with increased frequency in SICs, reflecting
a representative sample.
TLR-4 is a surface recognition receptor present on corneal
and conjunctival cells. In the presence of Acanthamoeba,
in vivo and in vitro models both show activation of TLR-4
receptor.40 In mouse models of AK, TLR-4 is also involved in
initiating the cytokine complex.40 It is likely that in patients
with AK, decreased recognition of Acanthamoeba allows a
greater inoculum load into the cornea with dysregulation
of the cytokine response, increasing disease severity. TLR-
4 is primarily associated with a pro-inflammatory response,
however, chronic activation of TLR-4 can lead to an anti-
inflammatory response in some circumstances.41 If this is
the case in AK, patients with milder disease may be able to
mount this anti-inflammatory response, whereas those with
the SNP and more severe disease may not, leading to chronic
hyperinflammation.
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A study of patients with bacterial keratitis in India found
higher carriage of TLR-4 rs4986791 SNP compared with
healthy controls.18 However, another study did not find an
association in rs4986790 (in LD with rs4986791) between
CL patients with bacterial keratitis compared with healthy
CL wearing controls in a Caucasian population.14 The differ-
ences in results in these two studies are intriguing, but
may be attributable to the rarity of the minor alleles. Inter-
estingly, carriers of TLR-4 SNPs have been shown to have
a decreased response to endotoxins in several studies.42,43
Of note, patients with TLR-4 SNPs show a blunted airway
response to inhalation of lipopolysaccharide (LPS).42 The
minor (T) allele of rs4986791 is associated with lower TLR-4
expression in blood plasma of a large German cohort, which
is replicated in a Arab and Asian cohort of healthy individ-
uals.44
Three Th17-related genes were associated with SICs in
this study, IL-1β, IL-23R, and IL-22. IL-1β and IL-22 are proin-
flammatory cytokines and associated with the differentia-
tion of CD4+ T cells into effector Th17 cells. For IL-22, the
SNP (rs1179251), as for CXCL8 (encodes IL-8) was protec-
tive. IL-22 tear fluid protein was also expressed more often
in this cohort of patients with AK who experienced severe
disease, as for IL-8.28 However, we did not find an associa-
tion between IL-22 tear protein levels and rs1179251 geno-
types (P = 0.07). To our knowledge, there are no studies that
correlate IL-22 protein to rs1179251. Of note is that serum
IL-22 protein is increased in idiopathic scleritis.45 A study
of IL-22 gene variations in autoimmune patients found the
CC wild type genotype was associated with Graves’ ophthal-
mopathy, conferring protection by the minor allele, similar
to our findings.46 Serum levels of IL-22 are associated with
the minor allele of rs2227484,47 and stimulated peripheral
blood mononuclear cells (PMBC) from patients carrying the
minor allele of rs2227473 produce more IL-22.48 However,
both these SNPs are in the promotor region of the gene,
whereas rs1179251 is in intron 4, rendering it difficult to
draw comparisons.
In alignment with other cytokines in this study, the signif-
icant detection of SNP in IL-1β (rs16944) is associated with
a lower risk of SICs. This SNP minor allele is associated
with increased gene expression in PBMCs.49 However. IL-1β
tear protein was not detectable in any of the tear samples
from AK cases or nonaffected healthy controls in this current
study population.28 This SNP and others in IL-1β have been
associated with susceptibility to early onset periodontitis50
and osteoarthritis.51 In a previous study in a Caucasian
population, an association was not found with IL-1β SNPs
between patients with CL associated bacterial keratitis and
healthy CL wearing controls.14 Further work is required to
understand the role of IL-1β in AK.
For IL-23R rs11209026, carriage of the A allele was asso-
ciated with a 6 times increased risk of SICs. The presence
of the A allele increases expression of the soluble form
of IL-23R mRNA (which then functions as a decoy recep-
tor) and thus impairs the function of IL-23 in its ability to
promote and maintain Th-17 cells.52 This may mean that the
Th-17 responses observed in an animal model of AK23 are
hampered in patients with this SNP.
There are several limitations of this study, in particular
the sample size. Although this is a rare disease and we
have a relatively large sample size per se, this limits power.
In addition, the small sample size did not enable a more
comprehensive analysis, such as genomewide association
study (GWAS) or exome screening. Similarly, we have not
made a correction for multiple testing of the 58 SNPs. All
of the SNPs analyzed in this study had a priori hypothesis
of association based on previous literature, but none reach
significance under strict multiple testing criteria, despite the
large effect sizes in many instances. Replication of these find-
ings in similar, but independent, cohorts is critical and meta-
analyses will likely be required to reach true statistical signif-
icance. Another limitation in this rare cohort was the self-
report of ethnicity, which was completed poorly by partic-
ipants (76/105, 72% identified ethnicity), however, 70/76,
92% identified as Caucasian. In a previous genetic study of
bacterial keratitis in CL wearers at Moorfields Eye Hospital in
2012, 82% were Caucasian,14 adding certainty that the cohort
in this current study is predominantly Caucasian.
Nevertheless, the study author’s clinical experience in
this area meant a very well phenotyped cohort. In addi-
tion, a well-matched cohort in terms of sex and age between
the SICs and non-SIC groups were recruited. Our results
are further strengthened by an earlier published tear fluid
protein study carried out on the same patient cohort.28
In summary, our study has highlighted the importance of
innate and Th17 immunity in patients with AK. A study of
gene expression in late stage bacterial and fungal kerati-
tis also found persistence of innate immune pathways.53
Further work will be important to define cause and effect
in tissue and animal models.
Furthermore, this study demonstrates that genetic screen-
ing of patients with AK for the presence of these SNPs is
viable and could predict the risk of patients developing the
severe inflammatory complications of the disease. The pres-
ence of these SNPs in an individual patient could assist clin-
icians managing AK by identifying patients susceptible to
developing SICs in whom the prompt treatment of inflam-
mation can be expected to improve outcomes.
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